Association between osteoporosis and hepatitis B cirrhosis: a case-control study.
Adult
Aged
Bone Density
Bone Diseases, Metabolic
/ epidemiology
Case-Control Studies
China
/ epidemiology
Collagen Type I
/ blood
Hepatitis B, Chronic
/ epidemiology
Humans
Incidence
Liver Cirrhosis
/ epidemiology
Male
Middle Aged
Osteocalcin
/ blood
Osteoporosis
/ epidemiology
Parathyroid Hormone
/ blood
Peptides
/ blood
Vitamin D
/ blood
Liver cirrhosis
bone density
chronic
hepatitis B
osteopenia
osteoporosis
Journal
African health sciences
ISSN: 1729-0503
Titre abrégé: Afr Health Sci
Pays: Uganda
ID NLM: 101149451
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
entrez:
16
8
2021
pubmed:
17
8
2021
medline:
26
4
2022
Statut:
ppublish
Résumé
Hepatitis B virus (HBV)-related cirrhosis is associated with decreased bone mineral density (BMD); however, the mechanism is yet unknown. To assess the incidence of osteoporosis in patients with HBV-associated cirrhosis and relevant mechanisms. A total of 80 hospitalized patients with HBV-associated cirrhosis and 80 healthy controls were enrolled. The levels of serum osteocalcin, total procollagen type 1 amino-terminal propeptide, β-C-terminal telopeptide of type I collagen (β-CTX), and 25-hydroxy vitamin D3 (25(OH)D3) was evaluated in the cirrhosis group. The BMDs of the lumbar spine (P<0.001) and hip joints (P=0.015) in the cirrhosis group were significantly lower than those in the controls. The incidence of osteoporosis in the cirrhosis group was significantly higher than that in the control group (P<0.001). Compared to the patients of the Child-Pugh grade A and B, the BMD of lumbar spine and 25(OH)D3 was significantly decreased in patients of grade C, while β-CTX was elevated. Patients in the cirrhosis group faced a higher risk of osteoporosis as compared to the controls(P<0.001). Enhanced bone resorption accounted for increased risk of osteoporosis in severe cirrhosis. Thus, HBV-associated cirrhosis was a risk factor for osteoporosis.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Hepatitis B virus (HBV)-related cirrhosis is associated with decreased bone mineral density (BMD); however, the mechanism is yet unknown. To assess the incidence of osteoporosis in patients with HBV-associated cirrhosis and relevant mechanisms.
METHODS
METHODS
A total of 80 hospitalized patients with HBV-associated cirrhosis and 80 healthy controls were enrolled. The levels of serum osteocalcin, total procollagen type 1 amino-terminal propeptide, β-C-terminal telopeptide of type I collagen (β-CTX), and 25-hydroxy vitamin D3 (25(OH)D3) was evaluated in the cirrhosis group.
RESULTS
RESULTS
The BMDs of the lumbar spine (P<0.001) and hip joints (P=0.015) in the cirrhosis group were significantly lower than those in the controls. The incidence of osteoporosis in the cirrhosis group was significantly higher than that in the control group (P<0.001). Compared to the patients of the Child-Pugh grade A and B, the BMD of lumbar spine and 25(OH)D3 was significantly decreased in patients of grade C, while β-CTX was elevated. Patients in the cirrhosis group faced a higher risk of osteoporosis as compared to the controls(P<0.001).
CONCLUSIONS
CONCLUSIONS
Enhanced bone resorption accounted for increased risk of osteoporosis in severe cirrhosis. Thus, HBV-associated cirrhosis was a risk factor for osteoporosis.
Identifiants
pubmed: 34394221
doi: 10.4314/ahs.v20i4.13
pii: jAFHS.v20.i4.pg1610
pmc: PMC8351827
doi:
Substances chimiques
Collagen Type I
0
Parathyroid Hormone
0
Peptides
0
Osteocalcin
104982-03-8
Vitamin D
1406-16-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1610-1616Informations de copyright
© 2020 Zhang Y et al.
Références
J Hepatol. 2014 Aug;61(2):210-8
pubmed: 24713185
Hepatology. 2016 Jan;63(1):261-83
pubmed: 26566064
Osteoporos Int. 2011 Feb;22(2):391-420
pubmed: 21184054
J Bone Miner Metab. 2016 Jul;34(4):367-79
pubmed: 26747614
N Engl J Med. 2007 Jul 19;357(3):266-81
pubmed: 17634462
Clin Res Hepatol Gastroenterol. 2018 Sep;42(4):368-377
pubmed: 29551613
PLoS One. 2018 Mar 15;13(3):e0194418
pubmed: 29543880
Eur J Clin Invest. 2014 Dec;44(12):1206-14
pubmed: 25331234
World J Gastroenterol. 2014 Jul 28;20(28):9427-38
pubmed: 25071337
Dig Dis Sci. 2000 Jul;45(7):1392-9
pubmed: 10961720
Crit Rev Eukaryot Gene Expr. 2001;11(1-3):199-226
pubmed: 11693961
Hepatology. 1998 Sep;28(3):695-9
pubmed: 9731561
J Clin Endocrinol Metab. 2004 Sep;89(9):4325-30
pubmed: 15356028
Hepatology. 2007 Oct;46(4):1271-8
pubmed: 17886334
Methods Mol Biol. 2014;1155:109-23
pubmed: 24788177
World Health Organ Tech Rep Ser. 1994;843:1-129
pubmed: 7941614
Gut. 2002 Feb;50 Suppl 1:i1-9
pubmed: 11788576
World J Gastroenterol. 2009 Jul 28;15(28):3516-22
pubmed: 19630107
Hepatology. 2011 Dec;54(6):2104-13
pubmed: 21837749
Sci Rep. 2016 Feb 04;6:19877
pubmed: 26842849
Medicine (Baltimore). 2015 Dec;94(50):e2276
pubmed: 26683953
J Biol Chem. 2019 May 10;294(19):7850-7863
pubmed: 30923130
J Hepatol. 2018 Sep;69(3):697-704
pubmed: 29673756
J Biol Chem. 2002 Jan 25;277(4):2695-701
pubmed: 11723115
Hepat Mon. 2015 Apr 25;15(4):e26871
pubmed: 25977695
Liver Int. 2015 Oct;35(10):2294-300
pubmed: 25757956
Lancet. 2016 Oct 8;388(10053):1459-1544
pubmed: 27733281